Meanwhile, there was more encouraging news for the UK's science base after it emerged that the country's research teams have won £500 million in research grants from the EU after being excluded from ...

That is according to the chief executive of the American Association for the Advancement of Science (AAAS), Sudip Parikh, who ...

Leela Barham uses the very latest data – running up to November 2023 – to take stock of NICE’s Single Technology Appraisal (STA) recommendations on orphan drugs versus non-orphans.

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate. The company said that ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD), setting it on course to become the first non-steroidal ...

PT: How does pharma deal with diverse geographies during launch? AH: This is difficult! Local and national reimbursement environments vary significantly by country and many will reference ...

Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson's disease which is currently in early-stage clinical testing.

The Biophysics for Drug Discovery Summit is the definitive, industry-dedicated forum bringing you the latest advancements, discoveries, applications and transferrable lessons of utilizing ...

A long-awaited report from the US Federal Trade Commission (FTC) on pharmacy benefit managers (PBMs) is out – and will make uncomfortable reading for the pharma supply chain middlemen.

The 2023 Transdermal and Microneedle Drug Delivery Conference will explore real world applications of microneedles in drug delivery and strategies for advanced and user-centric device design.

Astellas has shored up the competitive profile of Izervay as a treatment for eye disorder geographic atrophy (GA), getting FDA approval for an extended treatment duration. The US regulator turned ...

Even before COVID-19 pushed access to an all-time low of roughly 20%, access has been declining for more than a decade. Post-pandemic, many think it remains lower. Yet, analysis of 600 million ...